MUBuy
Micron Technology
Price (1y)
Fair price check
5 different valuation methods each estimate what MU should be worth, then we compare to today's price.
- EV/EBITDAUndervaluedthinks it's a bargain — estimates $1750.40, about 142% above today
- P/E multiplesUndervaluedthinks it's a bargain — estimates $1097.53, about 51% above today
- P/B multiplesOvervaluedthinks it's expensive — estimates $497.39, about 31% below today
- Graham (defensive)Outlierestimate looks unreliable — estimates $37.28 — likely unreliable
- DCF (2-stage)Outlierestimate looks unreliable — estimates $27.51 — likely unreliable
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
| Method | Value |
|---|---|
| Graham (defensive) | $37.28 |
| P/E multiples(vs sub industry peers) | $1097.53 |
| P/B multiples(vs sub industry peers) | $497.39 |
| EV/EBITDA(vs sub industry peers) | $1750.40 |
| Residual Income | skipped |
| DCF (2-stage) | $27.51 |
- extreme graham estimate
- extreme dcf estimate
- value trap risk
Median of all applicable methods (current price $724.66). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Pillar breakdown
8 dimensions, each scored 0–100 against the universe
- QualityProfit margins & asset efficiency72Strong
- ValuePrice vs fundamentals44Weak
- GrowthRevenue & earnings trajectory43Weak
- MomentumRecent price strength86Strong
- HealthBalance sheet & solvency92Strong
- ProfitabilityROE, ROA, ROIC74Strong
- TechnicalTrend & volatility signals72Strong
- RiskVolatility & drawdown profile53Decent
Pillars not shown: Sentiment, ML (Phase 5+).
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $817.22B |
| Revenue (TTM) | $58.12B |
| Net income (TTM) | $24.11B |
| Operating cash flow (TTM) | $30.65B |
| CapEx (TTM) | $20.37B |
| Free cash flow (TTM)CFO − CapEx | $10.28B |
| Total assets | $101.51B |
| Total liabilities | $29.05B |
| Stockholders' equity | $72.46B |
| Cash & equivalents | $13.91B |
| Shares outstanding | 1.13B |
| EPS (basic) | $16.91 |
| EPS (diluted) | $16.68 |
| P/E ratio (TTM) | 33.89 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-03-19
- Latest period end
- 2026-03-11
- Filing lag
- 58 days
- Missing metrics
- 1(accounts_payable)
Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.